First Tracks Biotherapeutics Reports Third-Quarter 2026 Results and Business Update
The company said ANB033 achieved a statistically significant and clinically meaningful protective effect; the available report is truncated before providing further details.
Story updates
09:17:32 PM UTC
SquawkNews
First Tracks Biotherapeutics said ANB033 showed statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in a Phase 1b gluten-challenge cohort. It anticipates celiac mucosal-healing results in Q1 2027 and eosinophilic esophagitis results in Q…
09:25:34 PM UTC
SquawkNews
First Tracks Biotherapeutics reported a third-quarter 2026 net loss of $31.4 million, compared with $41.9 million in the prior-year quarter. Operating expenses were $32.8 million, and the company reported a net loss per share of $0.88. Cash, cash equivalents and investments were $155.6 million at q…